We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novo Nordisk’s Weight Loss Drug Saxenda Gets FDA Panel Recommendation

Novo Nordisk’s Weight Loss Drug Saxenda Gets FDA Panel Recommendation

Novo-Nordisk.gif
September 18, 2014

An FDA advisory panel last week overwhelmingly recommended approval of Novo Nordisk’s latest weight-loss drug Saxenda.

Members of the agency’s Endocrinologic and Metabolic Drugs Advisory Committee voted 14-1 support approval of Saxenda (liraglutide 3 mg) as an adjunct to diet and exercise in adults with a BMI of 30 or more, or 27 or more with at least one weight-related comorbidity.

The positive recommendation was based on results from the company’s Phase IIIa trial of 5,000 overweight adults, as well as data from Novo Nordisk’s other liraglutide product, Victoza (liraglutide 1.8 mg), which was approved in 2010.

As of February, Victoza was the leading weight-loss drug on the market, with two-thirds of all sales.

While Victoza is indicated for controlling blood sugar in patients with type II diabetes, further analyses of liraglutide showed that the higher dose is required to induce clinically meaningful weight loss, Novo Nordisk spokeswoman Sharon Corbitt said. Liraglutide is a GLP-1 agonist that mimics a hormone that is released to control hunger when a person eats.

Other manufacturers are eyeing the GLP-1 drug market, which was roughly $3 billion worldwide and could grow soon to $5 billion, according to ISI Group estimates in February. Eli Lilly and Boehringer Ingelheim earlier this year submitted their dulaglutide drug, which has shown to be equal to Victoza in Phase III trials. That drug is still under FDA review.

Meanwhile, the FDA last week approved Takeda and Orexigen’s Contrave (extended-release naltrexone HCl and bupropion HCl) for the same indication that Novo Nordisk is seeking in Saxenda. Contrave was the first weight-loss drug to gain FDA approval since Vivus’ Qsymia (phentermine/topiramate) and Arena Pharmaceutical’s Belviq (lorcaserin HCl) were cleared in 2012.

The FDA doesn’t have to follow the recommendation of its advisory panels, but usually does. Saxenda’s PDUFA data is October 20. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Drugs Submissions and Approvals

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Biden Offers Drug Supply Chain Fixes, but Think Tank Says Government Isn’t Doing Enough

    • FDA Gives Green Light to Medtronic’s Symplicity Renal Denervation System

    • T-cell Malignancy From CAR-T Cell Immunotherapies Gets FDA Investigation

    • Vivos Sleep Apnea Oral Device Gets FDA Nod While Philips Wrestles With Yet Another CPAP Safety Issue

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing